Boston Family Office LLC Invests $243,000 in Kenvue Inc. (NYSE:KVUE)

Boston Family Office LLC purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,403 shares of the company's stock, valued at approximately $243,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Grove Bank & Trust increased its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue during the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC raised its holdings in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc boosted its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.9 %

KVUE stock traded down $0.23 during midday trading on Thursday, hitting $23.65. The company's stock had a trading volume of 21,703,204 shares, compared to its average volume of 16,767,870. The company's fifty day moving average price is $22.56 and its 200 day moving average price is $22.48. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market capitalization of $45.19 billion, a P/E ratio of 44.61, a PEG ratio of 2.62 and a beta of 1.25.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on KVUE shares. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group raised their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Finally, Barclays lifted their price target on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.